Born in Buenos Aires, Argentina, Dr. Carlos Kase earned his MD degree in Santiago, Chile, from the Catholic University of Chile in May 1967. He pursued further training in Neurology and Vascular Neurology at Massachusetts General Hospital in Boston from 1972-1973, and 1977-1978. Dr. Kase is board-certified by the American Board of Psychiatry and Neurology in Neurology (1980) and also board-certified in the subspecialty of Vascular Neurology (2005).
Dr. Kase joined the Department of Neurology at Boston University School of Medicine in 1984, where he is currently Professor of Neurology and Neurologist-in-Chief, Boston Medical Center. Prior to this, he joined Dr. J.P. Mohr in forming the Neurology Department at the University of South Alabama in Mobile, Alabama in 1978.
Dr. Kase’s professional and research interests are in cerebrovascular diseases, with a special interest in intracerebral hemorrhage, carotid artery disease and lacunar infarctions. He has been actively involved in performing clinical studies and clinico-pathologic correlations in intracerebral hemorrhage and cerebral infarction. His research activities have included participation in multicenter NIH-sponsored studies such as the Stroke Data Bank (NINCDS), the Warfarin Aspirin Recurrent Stroke Study (WARSS), the Warfarin vs. Aspirin for Symptomatic Intracranial Disease (WASID) Study, the Secondary Prevention of Small Subcortical Strokes (SPS3) study, and the Insulin Resistance Intervention after Stroke (IRIS) trial, as well as in a number of therapeutic clinical trials. In addition, Dr. Kase has participated in the Framingham Study since 1984, where he has led a number of important epidemiological studies on risk factors in stroke.
Dr. Kase has received numerous distinguished honors for his work in cerebrovascular disease, including Honorary Membership to the Spanish Society of Neurology and the Mexican Association of Cerebrovascular Disease. In 2001, he received the C. Miller Fisher Award for Excellence in Stroke, awarded by the American Stroke Association, Massachusetts Affiliate. In 2002 he was awarded the title of Doctor Honoris Causa from the Universidad de Santiago de Compostela, Santiago de Compostela, Spain.
Dr. Kase was recognized as a “Top Doctor” in Neurology by Boston Magazine in 2009, 2010, 2011, 2012 and by U.S. News and World Report in 2011.
- Active Staff Privileges, Neurology, Boston Medical Center
- Pontificia Universidad Católica de Chile, MD
- Pontificia Universidad Católica de Chile, BS
- Published on 7/19/2017
Shoamanesh A, Pearce LA, Bazan C, Catanese L, McClure LA, Sharma M, Marti-Fabregas J, Anderson DC, Kase CS, Hart RG, Benavente OR. Microbleeds in the Secondary Prevention of Small Subcortical Strokes Trial: Stroke, mortality, and treatment interactions. Ann Neurol. 2017 Aug; 82(2):196-207. PMID: 28681535.
- Published on 6/24/2017
Aparicio HJ, Himali JJ, Beiser AS, Davis-Plourde KL, Vasan RS, Kase CS, Wolf PA, Seshadri S. Overweight, Obesity, and Survival After Stroke in the Framingham Heart Study. J Am Heart Assoc. 2017 Jun 24; 6(6). PMID: 28647687.
- Published on 6/23/2017
Aparicio HJ, Petrea RE, Massaro JM, Manning WJ, Oyama-Manabe N, Beiser AS, Kase CS, D'Agostino RB, Wolf PA, Vasan RS, DeCarli C, O'Donnell CJ, Seshadri S. Association of descending thoracic aortic plaque with brain atrophy and white matter hyperintensities: The Framingham Heart Study. Atherosclerosis. 2017 Oct; 265:305-311. PMID: 28673480.
- Published on 6/22/2017
Perloff MD, Patel NS, Kase CS, Oza AU, Voetsch B, Romero JR. Cerebellar stroke presenting with isolated dizziness: Brain MRI in 136 patients. Am J Emerg Med. 2017 Nov; 35(11):1724-1729. PMID: 28687453.
- Published on 3/18/2017
Stefanidou M, Das RR, Beiser AS, Sundar B, Kelly-Hayes M, Kase CS, Devinsky O, Seshadri S, Friedman D. Incidence of seizures following initial ischemic stroke in a community-based cohort: The Framingham Heart Study. Seizure. 2017 Apr; 47:105-110. PMID: 28364691.
- Published on 2/3/2017
Dufouil C, Beiser A, McLure LA, Wolf PA, Tzourio C, Howard VJ, Westwood AJ, Himali JJ, Sullivan L, Aparicio HJ, Kelly-Hayes M, Ritchie K, Kase CS, Pikula A, Romero JR, D'Agostino RB, Samieri C, Vasan RS, Chêne G, Howard G, Seshadri S. Revised Framingham Stroke Risk Profile to Reflect Temporal Trends. Circulation. 2017 Mar 21; 135(12):1145-1159. PMID: 28159800.
- Published on 1/31/2017
Romero JR, Preis SR, Beiser A, Himali JJ, Shoamanesh A, Wolf PA, Kase CS, Vasan RS, DeCarli C, Seshadri S. Cerebral Microbleeds as Predictors of Mortality: The Framingham Heart Study. Stroke. 2017 Mar; 48(3):781-783. PMID: 28143923.
- Published on 1/12/2017
Lubitz SA, Yin X, McManus DD, Weng LC, Aparicio HJ, Walkey AJ, Rafael Romero J, Kase CS, Ellinor PT, Wolf PA, Seshadri S, Benjamin EJ. Stroke as the Initial Manifestation of Atrial Fibrillation: The Framingham Heart Study. Stroke. 2017 Feb; 48(2):490-492. PMID: 28082669.
- Published on 1/10/2017
Hanley DF, Lane K, McBee N, Ziai W, Tuhrim S, Lees KR, Dawson J, Gandhi D, Ullman N, Mould WA, Mayo SW, Mendelow AD, Gregson B, Butcher K, Vespa P, Wright DW, Kase CS, Carhuapoma JR, Keyl PM, Diener-West M, Muschelli J, Betz JF, Thompson CB, Sugar EA, Yenokyan G, Janis S, John S, Harnof S, Lopez GA, Aldrich EF, Harrigan MR, Ansari S, Jallo J, Caron JL, LeDoux D, Adeoye O, Zuccarello M, Adams HP, Rosenblum M, Thompson RE, Awad IA. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet. 2017 Feb 11; 389(10069):603-611. PMID: 28081952.
- Published on 10/11/2016
Hanley DF, Thompson RE, Muschelli J, Rosenblum M, McBee N, Lane K, Bistran-Hall AJ, Mayo SW, Keyl P, Gandhi D, Morgan TC, Ullman N, Mould WA, Carhuapoma JR, Kase C, Ziai W, Thompson CB, Yenokyan G, Huang E, Broaddus WC, Graham RS, Aldrich EF, Dodd R, Wijman C, Caron JL, Huang J, Camarata P, Mendelow AD, Gregson B, Janis S, Vespa P, Martin N, Awad I, Zuccarello M. Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial. Lancet Neurol. 2016 Nov; 15(12):1228-1237. PMID: 27751554.
View 180 more publications: View full profile at BUMC